Ardelyx (ARDX) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Ardelyx, Inc (ARDX) PT Raised to $13 at H.C. Wainwright
February 23, 2024 6:08 AM ESTH.C. Wainwright analyst Ed Arce raised the price target on Ardelyx, Inc (NASDAQ: ARDX) to $13.00 (from $11.00) while maintaining a Buy rating.
The analyst comments "We project U.S. IBSRELA annual net sales growth of 84% in 2024. Yesterday, Ardelyx announced 2023 U.S. IBSRELA net sales for irritable bowel syndrome (IBS-C) of $80.1M, largely in-line with... More
